7/27/2011 | CVIG | S&P ups Genzyme notes
|
6/21/2011 | CVIG | Moody's ups Genzyme notes
|
5/26/2011 | CVIG | Moody's: Genzyme unchanged
|
5/24/2011 | IGLM | Genzyme launches consent solicitation for 3 5/8%, 5% senior notes
|
2/16/2011 | CVIG | Moody's may up Genzyme
|
2/10/2011 | CVIG | S&P places Genzyme on positive watch
|
12/31/2010 | CVIG | S&P affirms Genzyme
|
6/15/2010 | IG | New Issue: Genzyme prices $1 billion of notes in five-, 10-year tranches
|
6/15/2010 | IG | Market Commentary: Teva, Lincoln National, Pall price deals; BP keeps widening; new deals strong in trading
|
6/14/2010 | CVIG | Moody's rates Genzyme notes Baa2
|
6/14/2010 | IG | Market Commentary: Toyota Motor Credit sells bonds; Lincoln Financial pricing notes; Secondaries prove quiet
|
6/14/2010 | CVIG | S&P rates Genzyme notes A-
|
12/4/2008 | CVIG | S&P upgrades Genzyme
|
11/7/2008 | CV | Market Commentary: GM, Ford weaker after reported losses, cash burn; Sprint Nextel extends gains; Wyeth firm
|
10/22/2008 | CV | Genzyme to redeem $690 million of 1.25% convertibles on Dec. 1
|
1/15/2008 | IG | S&P lifts Genzyme
|
10/23/2007 | SS | Bioenvision no longer traded as merger with Genzyme concludes
|
10/22/2007 | SS | Bioenvision shareholders say yes to Genzyme merger deal
|
10/10/2007 | SS | Bioenvision, Genzyme file petition, get court's OK for Oct. 22 special meeting
|
10/1/2007 | SS | SCO Capital to vote against Genzyme acquisition of Bioenvision, plans to nominate new board members
|
9/27/2007 | SS | Genzyme will not increase price for Bioenvision
|
9/12/2007 | SS | SCO reiterates plan for Bioenvision; not in favor of Genzyme merger
|
9/6/2007 | SS | Elliott Associates to vote against merger of Genzyme, Bioenvision
|
7/10/2007 | SS | Genzyme completes tender offer for Bioenvision shares
|
7/3/2007 | SS | SCO calls on Bioenvision to abandon sale to Genzyme
|
7/2/2007 | SS | Genzyme extends tender for Bioenvision common, preferred stock
|
6/27/2007 | SS | Bioenvision shareholder reiterates disapproval of company's deal with Genzyme
|
6/5/2007 | SS | Bioenvision shareholders led by SCO Securities object to planned merger with Genzyme
|
5/30/2007 | SS | Market Commentary: Bioenvision climbs, Genzyme holds firms on deal opposition; Guitar Center gains further on sale hopes
|
5/29/2007 | SS | Genzyme's acquisition of Bioenvision builds on companies' oncology drug development
|
2/14/2007 | CV | Market Commentary: Genzyme, Transocean climb on results; Teva gains further on outlook; Archer Daniels Midland plans deal
|
10/31/2006 | BT | Bear Stearns prices Genzyme at $79
|
10/30/2006 | BT | Genzyme rated at buy by Merrill
|
10/27/2006 | BT | Market Commentary: Genzyme slides on deal buzz; Cadence, Achillion up; Aspreva falls; Vertex gains 18%; Critical off on PIPE
|
10/26/2006 | BT | Market Commentary: Achillion gains on debut; Cadence slips; DOV Pharma nosedives; Celgene better; Renovis falls 76%
|
10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
10/13/2006 | BT | Merrill keeps Genzyme at buy
|
10/13/2006 | BT | Genzyme rated at buy by Jefferies
|
10/12/2006 | BT | Genzyme reports increased Q3 revenue despite low Synvisc sales, awaits news on AnorMED merger
|
10/12/2006 | BT | Market Commentary: Genzyme gets AnorMED nod but hurt by 3Q; Nabi up 6% on asset sale; Trimeris off 13% on warning
|
10/11/2006 | BT | Market Commentary: Genentech slides, Xoma adds 8%; Genzyme eases; NitroMed sinks; Oscient gains; Northfield loses 3%
|
10/11/2006 | BT | Genzyme at buy rating from Jefferies
|
10/10/2006 | BT | Genzyme at buy by Merrill
|
10/10/2006 | BT | Market Commentary: AnorMED gains 5% as Genzyme bests Millennium bid; DOV sinks 9% on hiring HSBC, up after close
|
10/6/2006 | BT | Genzyme at buy by Merrill
|
10/6/2006 | BT | Market Commentary: Acorda up 10% as Elan, Biogen ease on Tysabri news; Panacos up on takeover; Memory up on PIPE
|
10/5/2006 | BT | Market Commentary: AnorMED up 7% as Genzyme boosts bid; GenVec gains 18%; Acorda rises; Light Sciences at bat
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
9/27/2006 | BT | Market Commentary: Nabi hires BofA, up after hours; Millennium off; BioSante dives 14.5%; BioCryst, Novavax gain
|
9/26/2006 | BT | AnorMED zooms after picking Millennium bid over Genzyme, but still seen firmly in play
|
9/26/2006 | BT | Market Commentary: AnorMED rockets on Millennium bid but still seen in play; Genzyme mum; Indevus slips on trial's end
|
9/15/2006 | BT | Genzyme at buy by Jefferies
|
9/14/2006 | BT | Genzyme reiterated at buy by Merrill
|
9/14/2006 | BT | Market Commentary: Threshold, Discovery Labs gain on widespread deal speculation; Curis better; Genzyme gains 3%
|
9/14/2006 | BT | Genzyme Campath study in multiple sclerosis meets co-primary endpoint
|
9/6/2006 | BT | Genzyme begins dosing in phase 3 study of Clolar in AML
|
9/1/2006 | BT | Jefferies rates Genzyme at buy
|
8/31/2006 | BT | Market Commentary: Genta off 15.5%; EpiCept off on PIPE; AnorMED steady; Diomed gains 28%; ImmunoGen higher
|
8/30/2006 | BT | Market Commentary: AnorMED snubs Genzyme bid; PDL higher as Roche backs out; Vasogen zooms 42%; Adeza up
|
8/30/2006 | BT | AnorMED rejects unsolicited Genzyme offer
|
8/15/2006 | BT | Genzyme says phase 2 trial shows tolevamer as effective as vancomycin in treatment of diarrhea
|
8/11/2006 | BT | Genzyme files for European approval of Synvisc in ankle, shoulder indications
|
7/27/2006 | BT | Genzyme launches diagnostic test for blood cancer
|
7/26/2006 | BT | Genzyme begins phase 2 trial of oral treatment for Gaucher disease
|
7/24/2006 | BT | Genzyme's Thymoglobulin receives FDA approval for additional manufacturing at Ireland plant
|
7/19/2006 | BT | Genzyme gets $350 million unsecured revolver
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
7/13/2006 | BT | Genzyme reiterated at buy by Merrill
|
7/13/2006 | BT | Jefferies rates Genzyme at buy
|
7/12/2006 | CV | Market Commentary: Genzyme, AAR jump outright with earnings; Archstone-Smith slows; Health Management gains further
|
7/12/2006 | BT | Genzyme second-quarter revenue up 19% to $793.4 million
|
7/12/2006 | BT | Market Commentary: Genzyme, Genentech 2Q results counteract; Curis retraces losses; Antigenics, CV, Cell Genesys up
|
7/11/2006 | BT | Genzyme at buy by Jefferies
|
7/10/2006 | BT | Merrill sees low EPS for Genyzme
|
6/26/2006 | BT | Merrill reiterates Genzyme at buy
|
6/12/2006 | BT | Genzyme moved to buy rating
|
5/17/2006 | BT | Genzyme releases two molecular tests for acute myelogenous leukemia
|
5/15/2006 | BT | Genzyme kept at neutral by Merrill
|
5/15/2006 | BT | Market Commentary: BioMimetic goes south; Sirna off on new deal; Cambridge rockets on buyout; Threshold extends fall
|
5/9/2006 | BT | Angiotech, Genzyme to develop surgical oncology treatments
|
5/1/2006 | BT | Genzyme maintains neutral rating from Merrill
|
5/1/2006 | BT | Jefferies puts Genzyme at buy
|
4/28/2006 | BT | FDA approves Genzyme's Myozyme for all patients with Pompe disease
|
4/24/2006 | CV | Market Commentary: Bausch and Lomb, Schlumberger get analysts' thumbs up; Halliburton, Medtronic shrug off reports
|
4/20/2006 | BT | Genzyme maintains buy rating from Jefferies
|
4/19/2006 | BT | Market Commentary: Genzyme crashes on miss; Nektar dips, ends higher; MannKind off; Icon better; Nabi adds another 4%
|
4/19/2006 | BT | Genzyme first-quarter revenue up 16% to $730.8 million
|
4/19/2006 | BT | Genzyme maintained at neutral by Merrill
|
4/18/2006 | BT | Jefferies puts Genzyme at buy
|
4/17/2006 | BT | Genzyme given outperform rating by Bear Stearns
|
4/10/2006 | BT | Genzyme starts humanitarian program to develop treatments for 'neglected' diseases
|
4/3/2006 | BT | Genzyme gets European Commission approval for Myozyme to treat Pompe disease
|
4/3/2006 | BT | Genzyme at neutral by Merrill
|
3/28/2006 | BT | Market Commentary: Advanced Magnetics gains 7%; Xoma slides; Seattle Genetics deal surfaces; Cephalon dips 2%
|
3/20/2006 | CV | Market Commentary: Kerzner buyout hurts hedge investors; BioMarin plans new deal; Time Warner Telecom offer seen as cheap
|
2/27/2006 | BT | Jefferies rates Genzyme at buy
|
2/23/2006 | BT | Genzyme abandons cardiac cell therapy trial
|
2/16/2006 | BT | Merrill maintains Genzyme at neutral
|
2/15/2006 | BT | Genzyme reports 2005 revenue of $2.7 billion, expects revenue of $3.1-$3.3 billion in 2006
|
2/10/2006 | BT | Genzyme gets buy rating from Jefferies
|
2/1/2006 | BT | Genzyme granted label change for thyroid cancer drug Thyrogen
|
1/31/2006 | BT | Market Commentary: Nuvelo zooms after deal; SGX cuts guidance, prices at low end; Sepracor soars; BioMarin bounces
|
1/27/2006 | BT | Genzyme's Myozyme receives positive recommendation from European regulatory committee
|
1/27/2006 | BT | PharmAust, Genzyme form alliance to provide peptide products, services to customers
|
1/17/2006 | BT | Genzyme maintained by Merrill at neutral
|
1/17/2006 | BT | Genzyme's biologics license application for Myozyme receives review extension
|
1/10/2006 | BT | Jefferies maintains Genzyme at buy
|
1/10/2006 | BT | Genzyme maintained by Merrill at neutral
|
12/21/2005 | BT | Genzyme acquires gene therapy assets from Avigen for $12 million plus potential royalties
|
12/19/2005 | BT | Crucell signs antibody license with Genzyme
|
12/8/2005 | BT | Dyax, Genzyme begin phase 3 trial of DX-88 for hereditary angioedema
|
12/6/2005 | BT | Genzyme chosen as preferred marketing partner for Third Wave's Invader UGT1A1 assay
|
11/22/2005 | BT | Cell Genesys sells San Diego manufacturing operation to Genzyme
|
11/9/2005 | BT | Merrill Lynch maintains Genzyme at neutral
|
11/8/2005 | BT | William Blair initiates Genzyme coverage at outperform
|
11/8/2005 | BT | Genzyme retains Synvisc Medicare code, reimbursement rate for 2006
|
11/7/2005 | BT | Market Commentary: Solid earnings fuel ViroPharma stock; Guidant sues Johnson & Johnson over proposed merger
|
11/7/2005 | CV | Market Commentary: Northwest, AMR higher as oil declines; Genzyme eases but Cephalon edges higher
|
11/2/2005 | BT | DiagnoCure licenses lung cancer genes from Genzyme
|
10/18/2005 | BT | Market Commentary: Amgen up; Abgenix, Cell Genesys lower; Chiron drops; Gilead sold on nice quarter; Genzyme seesaws
|
10/18/2005 | BT | Merrill Lynch maintains Genzyme at neutral
|
10/17/2005 | BT | Genzyme buy rating reiterated by Jefferies
|
10/3/2005 | BT | Genzyme maintained by Bear Stearns at market outperform
|
9/26/2005 | BT | Genzyme kept by Bear Stearns at outperform
|
9/16/2005 | BT | Genzyme reiterated by Jefferies at buy
|
9/16/2005 | BT | Genzyme maintained by Merrill at neutral
|
9/7/2005 | BT | Mature U.S. biotechs have stronger credit than industrials but weaker than Big Pharma, S&P says
|
7/29/2005 | BT | Genzyme kept by Jefferies at buy
|
7/28/2005 | BT | Genzyme kept by Merrill Lynch at neutral
|
7/20/2005 | CV | Market Commentary: Amgen rises in mixed convertibles trading as earnings reports roil GM, Kodak, boost Wyeth
|
7/18/2005 | CV | Market Commentary: Convertibles market pauses ahead of earnings; Genzyme falls amid mixed biotechs, Lucent, financials ease
|
7/15/2005 | BT | Genzyme should ultimately outperform Gilead, Merrill report says
|
7/14/2005 | BT | Market Commentary: Genentech active; CryoCor IPO trades up, sinks; Mylan prices tight, center; BioMarin off on follow-on
|
7/14/2005 | CV | Market Commentary: GM, Ford convertibles move up in active trade; AMD, Genzyme, airlines also gain, other sectors quiet
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
6/29/2005 | CV | Market Commentary: CV Therapeutics' new deal gains, supporting biotechs; Mirant trades in heavy volume; General Mills eases
|
6/29/2005 | BT | Market Commentary: CV Therapeutics, Lonza upsize convertibles, both higher in trade; Millennium gains on new CEO
|
6/17/2005 | BT | Market Commentary: Mylan Labs bond deal surfaces; Vertex up, Merck lags; Genentech rises; stem cell names watched
|
6/7/2005 | CV | S&P ups Genzyme view to positive
|
3/14/2005 | CV | Market Commentary: JetBlue a laggard as airline paper up; Delta bankruptcy fears weigh; PDLI gains; Aquila up; Xoma off
|
7/15/2004 | CV | Market Commentary: Caesars eases back to levels before Harrah's deal; EDS off 1.75-2.25 points on cut to junk
|
5/20/2004 | CV | Genzyme calls 3% convertibles
|
3/11/2004 | CV | New Issue: Merrill prices $25 million 7% callable Strides exchangeable for Genzyme
|
3/3/2004 | CV | S&P: Genzyme unaffected
|
3/3/2004 | CV | Market Commentary: Disney little changed on concerns besides Eisner; PSS soars to 106; Toys up on hoped-for store sales
|
2/2/2004 | CV | Market Commentary: El Paso, other power issues lower; Delta deal emerges as airlines' descent continues
|
12/9/2003 | CV | Genzyme greenshoe exercised, raising convertibles to $690 million
|
12/5/2003 | CV | Market Commentary: CenterPoint drops 2 points on unlikely asset sale to Reliant; JetBlue dives 7.5 on warning
|
12/4/2003 | CV | New Issue: Genzyme $600 million convertibles yield 1.25%, up 47.5%
|
12/4/2003 | CV | S&P rates new Genzyme convertibles BBB
|
12/4/2003 | CV | Market Commentary: Genzyme reoffered at 99.25, trades up to 100.25; other new issues active, but flat
|
12/3/2003 | CV | Genzyme $600 million convertible talked at 1.0-1.25%, up 47.5-52.5%
|
12/3/2003 | CV | Market Commentary: Dominion, Genzyme emerge; Concord soars to 111, slides to 105.25; Fairmont hits 104.5
|
7/28/2003 | CV | S&P rates new Health Management convertible
|
5/2/2003 | CV | Moody's puts GM on review
|
1/14/2003 | CV | Market Commentary: Some expect credit spread rally to begin leveling off; Oneok mandatory guidance emerges
|
12/20/2002 | CV | Market Commentary: Market quietly closes ahead of holiday-shortened weeks
|
6/20/2002 | CV | Market Commentary: Convertibles marked lower still in thin summer trading pattern
|
4/10/2002 | CV | Market Commentary: Duane Reade brings new deal in new structure; Biotechs, drugs higher on short covering
|
1/24/2002 | CV | Market Commentary: Awaiting Ford terms, convertibles flat as market watched Greenspan, Enron hearings
|
10/22/2001 | CV | Market Commentary: Convertibles gain with stocks, new deals keep coming
|